Clinical Report: ESMO Breast Cancer 2026 Highlights: Saci-IO HR+

Overview

The Saci-IO HR+ trial results were presented at the 2026 ESMO Breast Cancer Congress, focusing on the combination of sacituzumab govitecan with pembrolizumab in HR+/HER2− metastatic breast cancer. This trial aims to evaluate the efficacy of this combination after prior endocrine therapy.

Background

Hormone receptor-positive (HR+) breast cancer remains a significant clinical challenge, particularly in the metastatic setting. Current treatment paradigms emphasize the use of endocrine therapy combined with CDK4/6 inhibitors as first-line therapy. The exploration of novel combinations, such as sacituzumab govitecan and pembrolizumab, is crucial for improving outcomes in patients with HR+/HER2− metastatic breast cancer.

Data Highlights

No specific numerical data or trial results were provided in the source material.

Key Findings

• The Saci-IO HR+ study is a randomized phase II trial.
• The trial tests sacituzumab govitecan with or without pembrolizumab.
• It targets HR+/HER2− metastatic breast cancer after prior endocrine therapy.
• Current guidelines recommend endocrine therapy with CDK4/6 inhibitors as first-line treatment.
• Subsequent-line options include targeted combinations and antibody-drug conjugates.

Clinical Implications

The findings from the Saci-IO HR+ trial may inform treatment strategies for HR+/HER2− metastatic breast cancer.

Conclusion

The Saci-IO HR+ trial represents an important step in evaluating new treatment combinations for HR+/HER2− metastatic breast cancer. Continued research in this area is essential for advancing therapeutic options.

Related Resources & Content

1. American Society of Clinical Oncology Educational Book, 2026 -- Evolving Treatment Paradigms in Hormone Receptor–Positive, Human Epidermal Growth Factor 2–Negative Metastatic Breast Cancer
2. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial, PubMed, 2023
3. Study Details | NCT04448886 | Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC, ClinicalTrials.gov
4. The ASCO Post — SABCS 2025: High-Level Review of Select Data
5. The ASCO Post — SABCS 2025: High-Level Review of Select Data
6. The ASCO Post — SABCS 2025: High-Level Review of Select Data
7. The ASCO Post — SABCS 2025: High-Level Review of Select Data
8. SABCS 2025: High-Level Review of Select Data
9. Evolving Treatment Paradigms in Hormone Receptor–Positive, Human Epidermal Growth Factor 2–Negative Metastatic Breast Cancer | American Society of Clinical Oncology Educational Book
10. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial - PubMed
11. Study Details | NCT04448886 | Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC | ClinicalTrials.gov